



ASX Announcement

Monash IVF Group Limited (ASX: MVF)

23 December 2020

Proceedings against Monash IVF Group

Monash IVF Group Limited (ASX: MVF, the “Company” or “Monash IVF” or “Group”) has become aware that it and certain of its subsidiaries have been named as defendants in proceedings filed in the Supreme Court of Victoria in relation to, or in connection with, the Group’s non-invasive preimplantation genetic screening technology (Ni-PGT or cell-free PGT-A) (“Claim”). The Claim does not specify an amount of damages sought.

Ni-PGT is one of several genetic screening technologies utilised by the Company to test for aneuploidy embryos and was introduced in May 2019 as an addition to its genetic screening program. Ni-PGT is a complementary embryo screening technology to cell biopsy PGT-A and is generally used to screen for chromosomal abnormal embryos that previously could not be tested with cell biopsy PGT-A. Since the commencement of Ni-PGT in May 2019, it was utilised in a small proportion of total patient treatments at Monash IVF and was suspended in October 2020 following a twelve-month post implementation review (as previously noted in the 26 November 2020 AGM presentation).

As transparency and reliability are of utmost importance to Monash IVF, patients who have been impacted by the suspension of Ni-PGT, have been provided with goodwill and ex-gratia remediation treatment offers.

The earnings guidance given by the Company at the time of its AGM on 26 November 2020 incorporated the trading impact from the suspension of Ni-PGT and the ex-gratia remediation treatment offers noted above.

The Group has notified its insurers in relation to the Claim and will vigorously defend it.

The Company will continue to keep the market updated as appropriate.

Approved by the Board of Directors.

Michael Knaap

Chief Executive Officer and Managing
Director, Monash IVF Group
+61 3 9420 8235

Malik Jainudeen

Chief Financial Officer and Company
Secretary, Monash IVF Group
+61 3 9420 8235